Hologic Expands Cervical Cancer Screening Portfolio with FDA-Approved HPV Primary Test
Event summary
- Hologic's Aptima® HPV Assay received FDA approval for clinician-collected HPV primary screening on February 4, 2026.
- The assay is the only FDA-approved mRNA-based test designed to detect high-risk HPV infections leading to cervical cancer.
- Approval follows a large-scale study involving over 650,000 women across multiple U.S. health systems.
- Hologic now offers three major FDA-approved screening methods: Pap + HPV co-testing, Pap testing, and HPV primary testing.
The big picture
Hologic's FDA approval for its Aptima HPV Assay as a primary screening tool expands its cervical health portfolio, aligning with industry trends toward personalized and AI-enhanced diagnostic solutions. The approval underscores Hologic's commitment to advancing women's health through evidence-based innovations, positioning the company as a leader in cervical cancer prevention technologies.
What we're watching
- Market Adoption
- How quickly providers will integrate the Aptima HPV Assay into primary screening protocols, given existing co-testing preferences.
- Competitive Positioning
- Whether Hologic can leverage this approval to strengthen its market share against competitors in cervical cancer screening.
- Clinical Impact
- The pace at which real-world evidence confirms the assay's sensitivity and specificity in diverse patient populations.
Related topics